Download PDF
Aktuelle Rheumatologie 2023; 48(06): 389-394
DOI: 10.1055/a-2021-7668
Original Article

Adherence to Colchicine During Pregnancy in Familial Mediterranean Fever Patients: Reasons for Cessation and Outcomes from a Single-Centre Experience

Adhärenz zu Colchicin während der Schwangerschaft bei Patienten mit familiärem Mittelmeerfieber: Gründe für das Absetzen und Behandlungsergebnisse in einem einzigen Zentrum
İsmail Dogan
1   Rheumatology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
,
Serdar Can Güven
2   Rheumatology, Ankara City Hospital, Ankara, Turkey
,
Özlem Karakaş
2   Rheumatology, Ankara City Hospital, Ankara, Turkey
,
Esra Kayacan Erdoğan
2   Rheumatology, Ankara City Hospital, Ankara, Turkey
,
Sukran Erten
1   Rheumatology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Turkey
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Erratum: Adherence to Colchicine During Pregnancy in Familial Mediterranean Fever Patients: Reasons for Cessation and Outcomes from a Single-Centre ExperienceAktuelle Rheumatologie 2023; 48(06): e1-e1
DOI: 10.1055/a-2189-8554

Abstract

Objective To evaluate the adherence to colchicine treatment during pregnancy and lactation in our Familial Mediterranean fever (FMF) patients and investigate the reasons for non-adherence and consequences.

Methods Adult female FMF patients who were followed up in our rheumatology clinic and had a history of pregnancy after the diagnosis of FMF were consecutively enrolled to this cross-sectional study between November 2021 and June 2022. Only pregnancies occurring after the diagnosis of FMF were evaluated. Patients who did not stop using FMF treatment after pregnancy were considered to adhere to treatment.

Results In 50 patients, a total of 88 pregnancies and 58 live births were observed after the diagnosis of FMF. 37 (74%) had at least one completed pregnancy, and 13 (26.0) were pregnant during the study. Among the 37 patients, 34 had at least one live birth. No significant differences were observed when rates of patients with a history of at least one live birth, abortus, Cesarean section (C/S), preterm labor, stillbirth, intrauterine anomaly, congenital malformation and fetal growth retardation were compared between colchicine users and non-users. 60% of the patients adhered to colchicine treatment during pregnancy and 73.4% did so while breastfeeding. The most common reason for colchicine cessation was concerns regarding potential harm to the fetus (70%), followed by the presumption that colchicine is contraindicated in pregnancy (15%) as well as absence of FMF attacks (10%). The most common source of the patients’ opinion was a physician (60%).

Conclusions Both patients and attending physicians should be informed to be more adherent to colchicine to avoid adverse outcomes and FMF-related complications.

Key words

Familial Mediterranean fever - pregnancy - lactation - medication adherence

Schlüsselwörter

Familiäres Mittelmeerfieber - Schwangerschaft - Stillzeit - Medikamentenhaftung


Publication History

Article published online:
12 April 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Ozen S, Karaaslan Y, Ozdemir O. et al. Prevalence of juvenile chronic arthritis and familial Mediterranean fever in Turkey: a field study. J Rheumatol 1998; 25: 2445-9
    PubMedSearch in Google Scholar
  • 2 Ozdogan H, Ugulu S.. Familial Mediterranean Fever. La Presse Medicale 2019; 48: e61-e76
    CrossrefPubMedSearch in Google Scholar
  • 3 Ben-Chetrit E, Levy M.. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis 2003; 62: 916-9
    CrossrefPubMedSearch in Google Scholar
  • 4 Ofir D, Levy A, Wiznitzer A. et al. Familial Mediterranean fever during pregnancy: an independent risk factor for preterm delivery. Eur J Obstet Gynecol Reprod Biol 2008; 141: 115-8
    CrossrefPubMedSearch in Google Scholar
  • 5 Vh Ferm. Effect Of Transplacental Mıtotıc Inhıbıtors On The Fetal Hamster Eye. Anat Rec 1964; 148: 129-37
    CrossrefPubMedSearch in Google Scholar
  • 6 Indraratna PL, Virk S, Gurram D. et al. Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology (Oxford) 2018; 57: 382-387
    CrossrefPubMedSearch in Google Scholar
  • 7 Herscovici T, Merlob P, Stahl B. et al. Colchicine use during breastfeeding. Breastfeed Med 2015; 10: 92-5
    CrossrefPubMedSearch in Google Scholar
  • 8 Ozen S, Demirkaya E, Erer B. et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016; 75: 644-51
    CrossrefPubMedSearch in Google Scholar
  • 9 Livneh A, Langevitz P, Zemer D. et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997; 40: 1879-85
    CrossrefPubMedSearch in Google Scholar
  • 10 Zayed HS, Medhat BM, Seif EM.. Evaluation of treatment adherence in patients with Behçet's disease: its relation to disease manifestations, patients' beliefs about medications, and quality of life. Clin Rheumatol 2019; 38: 761-768
    CrossrefPubMedSearch in Google Scholar
  • 11 Horne R, Parham R, Driscoll R. et al. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflammatory Bowel Diseases 2009; 15: 837-844
    CrossrefPubMedSearch in Google Scholar
  • 12 Pasma A, Van’t Spijker A, Hazes J. et al. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Seminars in Arthritis and Rheumatism 2013; 43: 18-28
    CrossrefPubMedSearch in Google Scholar
  • 13 Horne R, Chapman SC, Parham R. et al. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One 2013; 8: e80633
    CrossrefPubMedSearch in Google Scholar
  • 14 Bilici Salman R, Babaoglu H, Satiş H. et al. Compliance of Familial Mediterranean Fever Patients With Regular Follow-up Visits and Associated Factors. J Clin Rheumatol 2022; 28: e77-e80
    CrossrefPubMedSearch in Google Scholar
  • 15 Tekgöz E, Çolak S, Çinar FI. et al. Non-adherence to colchicine treatment is a common misevaluation in familial Mediterranean fever. Turk J Med Sci 2021; 51: 2357-2363
    CrossrefPubMedSearch in Google Scholar
  • 16 Karaaslan Y, Dogan I, Omma A. et al. Compliance to colchicine treatment and disease activity in familial Mediterranean fever (FMF) patients in Middle/Black Sea Region of Turkey (in Çorum region). Pediatr Rheumatol 2015; 13 (Suppl. 1) P81
    CrossrefPubMedSearch in Google Scholar
  • 17 Ozdogan H, Ugurlu S, Hatemi G.. Colchicine compliance and amyloidosis. Pediatric Rheumatology 2013; 11
    CrossrefPubMedSearch in Google Scholar
  • 18 Ben-Chetrit E, Aamar S.. About colchicine compliance, resistance and virulence. Clin Exp Rheumatol 2009; 27 (2 Suppl 53) S1-3
    PubMedSearch in Google Scholar
  • 19 Melikoglu MA, Senel K.. Non-response to colchicine in familial Mediterranean fever should be identified accurately. Int J Rheum Dis 2017; 20: 2118-2121
    CrossrefPubMedSearch in Google Scholar
  • 20 Ozen S, Kone-Paut I, Gül A.. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum 2017; 47: 115-120
    CrossrefPubMedSearch in Google Scholar
  • 21 Diav-Citrin O, Shechtman S, Schwartz V. et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol 2010; 203: 144.e1-6
    CrossrefPubMedSearch in Google Scholar
  • 22 Rabinovitch O, Zemer D, Kukia E. et al. Colchicine treatment in conception and pregnancy: two hundred thirty-one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol 1992; 28: 245-6
    CrossrefPubMedSearch in Google Scholar
  • 23 Nabil H, Zayed A, State O. et al. Pregnancy outcome in women with familial Mediterranean fever. J Obstet Gynaecol 2012; 32: 756-9
    CrossrefPubMedSearch in Google Scholar
  • 24 Yasar O, Iskender C, Kaymak O. et al. Retrospective evaluation of pregnancy outcomes in women with familial Mediterranean fever. J Matern Fetal Neonatal Med 2014; 27: 733-6
    CrossrefPubMedSearch in Google Scholar
  • 25 Ben-Chetrit E, Ben-Chetrit A, Berkun Y. et al. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified?. Arthritis Care Res (Hoboken) 2010; 62: 143-8
    CrossrefPubMedSearch in Google Scholar
  • 26 Yazicioglu A, Turgal M, Yucel O. et al. Pregnancy outcome in women with familial Mediterranean fever: A retrospective analysis of 50 cases with a 10-year experience. Arch Rheumatol 2014; 29: 94-8
    CrossrefPubMedSearch in Google Scholar
  • 27 Cabili S, Livneh A, Zemer D. et al. The effect of pregnancy on renal function in amyloidosis of familial Mediterranean fever. Am J Reprod Immunol 1992; 28: 243-4
    CrossrefPubMedSearch in Google Scholar
  • 28 Bodur H, Yurdakul FG, Çay HF. et al. Familial mediterranean fever: assessment of clinical manifestations, pregnancy, genetic mutational analyses, and disease severity in a national cohort. Rheumatol Int 2020; 40: 29-40
    CrossrefPubMedSearch in Google Scholar
  • 29 Ben-Chetrit E, Scherrmann JM, Levy M.. Colchicine in breast milk of patients with familial Mediterranean fever. Arthritis Rheum 1996; 39: 1213-7
    CrossrefPubMedSearch in Google Scholar
  • 30 American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001; 108: 776-89
    CrossrefPubMed